Biohaven Pharmaceutical Holding Company Ltd. Share Price
Equities
BHVN
VGG111961055
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.97 USD | +1.12% | -0.05% | -74.33% |
04-25 | Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing | MT |
04-23 | Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO | MT |
Sales 2020 | 63.63 5.09K | Sales 2021 | 462.51 37.03K | Capitalization | 9.03B 723B |
---|---|---|---|---|---|
Net income 2020 | -767M -61.4B | Net income 2021 | -847M -67.8B | EV / Sales 2020 | 87,534,473 x |
Net Debt 2020 | 432M 34.6B | Net Debt 2021 | 860M 68.88B | EV / Sales 2021 | 21,377,123 x |
P/E ratio 2020 |
-6.56
x | P/E ratio 2021 |
-10.5
x | Employees | 928 |
Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 90.13% |
1 day | +1.12% | ||
Current month | -74.33% | ||
Current year | -74.33% |
Managers | Title | Age | Since |
---|---|---|---|
Paloma Moraleda
PSD | President | - | 02/10/22 |
Jon Blaskovich
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | 24/10/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paloma Moraleda
PSD | President | - | 02/10/22 |
Gastón Ortega
BRD | Director/Board Member | - | 02/10/22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.97% | 0 M€ | 0.00% | - | |
0.11% | 9 M€ | -.--% | - | |
0.06% | 736 M€ | +6.09% |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 38.97 | +1.12% | 948,357 |
25/04/24 | 38.54 | -0.46% | 1,850,774 |
24/04/24 | 38.72 | -2.25% | 971,893 |
23/04/24 | 39.61 | +3.34% | 2,087,194 |
22/04/24 | 38.33 | -1.69% | 1,132,256 |
Delayed Quote Nyse, April 26, 2024 at 09:00 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-74.33% | 541M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- BHVN Stock